Randomized trial or adjuvant tamoxifen pour years vs two years in node positive breast cancer women.

被引：0
|
作者：
Gallén, M [1 ]
Alonso, C [1 ]
Ojeda, B [1 ]
Viladíu, P [1 ]
Beltrán, W [1 ]
Borrás, J [1 ]
Tusquets, I [1 ]
Arcusa, A [1 ]
Barnadas, A [1 ]
Bastús, R [1 ]
Balil, A [1 ]
Batiste-Alentorn, E [1 ]
Guasch, I [1 ]
Garau, I [1 ]
Boleda, W [1 ]
Badia, A [1 ]
机构：
[1] Hosp Del Mar, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 50 条
  • [41] aTTom (adjuvant Tamoxifen-To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-Preliminary results
    Gray, R. G.
    Rea, D. W.
    Handley, K.
    Marshall, A.
    Pritchard, M. G.
    Perry, P.
    Earl, H. M.
    Poole, C. J.
    Salman, A.
    Lee, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer - A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone and tamoxifen plus fluoxymesterone in women above 65 years of age
    Rose, C
    Kamby, C
    Mouridsen, HT
    Andersson, M
    Bastholt, L
    Moller, KA
    Andersen, J
    Munkholm, P
    Dombernowsky, P
    Christensen, IJ
    BREAST CANCER RESEARCH AND TREATMENT, 2000, 61 (02) : 103 - 110
  • [43] Two years of adjuvant tamoxifen in premenopausal patients with breast cancer:: a randomised, controlled trial with long-term follow-up
    Rydén, L
    Jönsson, PE
    Chebil, G
    Dufmats, M
    Fernö, M
    Jirström, K
    Källström, AC
    Landberg, G
    Stål, O
    Thorstenson, S
    Nordenskjöld, B
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (02) : 256 - 264
  • [44] Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer
    Rea, D. W.
    Gray, R. G.
    Bowden, S. J.
    Handley, K.
    Earl, H. M.
    Poole, C. J.
    Bates, T.
    Dewar, J. A.
    Raytor, Z.
    Lee, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S402 - S402
  • [45] Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC).
    Vakaet, L. A.
    Buyse, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S108 - S109
  • [46] CONTROLLED TRIAL OF TAMOXIFEN AS SINGLE ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST-CANCER - ANALYSIS AT 6 YEARS
    BAUM, M
    LANCET, 1985, 1 (8433): : 836 - 840
  • [47] A RANDOMIZED TRIAL OF ADJUVANT AMINOGLUTETHIMIDE VERSUS PLACEBO IN POSTMENOPAUSAL PATIENTS WITH NODE POSITIVE BREAST-CANCER
    JONES, AL
    POWLES, TJ
    COOMBES, RC
    SMITH, IE
    EASTON, D
    BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 521 - 522
  • [48] BONE-MINERAL DENSITY IN WOMEN WITH BREAST-CANCER TREATED WITH ADJUVANT TAMOXIFEN FOR AT LEAST 2 YEARS
    LOVE, RR
    MAZESS, RB
    TORMEY, DC
    BARDEN, HS
    NEWCOMB, PA
    JORDAN, VC
    BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (03) : 297 - 301
  • [49] GUYS MANCHESTER CMF TRIAL IN NODE POSITIVE BREAST-CANCER - AN UPDATE AT 8 YEARS
    OREILLY, SM
    RICHARDS, MA
    HOWELL, A
    RUBENS, RD
    BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 522 - 522
  • [50] Adjuvant systemic therapy for women with node-positive breast cancer
    O'Reilly, SE
    Allan, SJ
    Shenkier, TN
    Gelmon, KA
    Levine, MN
    Olivotto, IA
    Fields, ALA
    Bowman, DM
    Bouchard, F
    McGregor, M
    Jolivet, J
    Pritchard, KI
    Verma, S
    Arjane, GA
    Ayoub, J
    Champion, PE
    Davis, ML
    Hicks, S
    Hiller, J
    Hiscock, J
    Liem, SK
    Mohamed, MF
    Tomiak, EM
    Warner, E
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1998, 158 : S52 - S64
12345